Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14779934 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMKMT2ACYP3A4CYP2C19 | |
| SCHEMBL13747805 | 0.84 | DPP4 (0.53) | DPP4DPP8DPP9KMT2ACYP3A4 | |
| SCHEMBL4464719 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2PKMKMT2ACYP3A4CYP2C19 | |
| SCHEMBL4464708 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2PKMKMT2ACYP3A4CYP2C19 | |
| SCHEMBL6443903 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2PKMDPP4DPP8DPP9 | |
| SCHEMBL23050302 | 0.79 | CTSK (0.53) | SMN1; SMN2PKMKMT2ATSHR | |
| SCHEMBL7718204 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2PKMKMT2ACYP3A4CYP2C19 | |
| SCHEMBL21142539 | 0.77 | SMN1; SMN2 (0.66) | SMN1; SMN2PKMKMT2AHTT | |
| SCHEMBL16580220 | 0.77 | SMN1; SMN2 (0.66) | SMN1; SMN2PKMKMT2AHTT | |
| SCHEMBL26820888 | 0.76 | CCR1 (0.61) | PKMKMT2ACYP3A4CYP2C19CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | SMN1; SMN2 3178/4885PKM 2838/4885DPP4 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.